IDiyas

For the Inventor, By the Inventor

Gaithersburg, MD, United States of America

Reinhard Ebner

USPTO Granted Patents = 55 

 

Average Co-Inventor Count = 4.5

ph-index = 16

Forward Citations = 615(Granted Patents)

Forward Citations (Not Self Cited) = 571(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Gatihersburg, MD (US) (2011)
  • Gaithersburg, MD (US) (2001 - 2014)

Company Filing History:

goldMedal54 out of 676 
 
Human Genome Sciences, Inc.
 patents
silverMedal1 out of 1 
 
Combimab, Inc.
 patent

Years Active: 2001-2014

Loading Chart...
Loading Chart...
55 patents (USPTO):Explore Patents
1. 8748575 - Therapeutic peptides (2014-06-10),
2. 8303951 - Neutrokine-alpha antibodies and methods of use thereof (2012-11-06),
3. 8231873 - Methods of treatment using antibodies to Neutrokine-alpha (2012-07-31),
4. 8212004 - Neutrokine-alpha fusion proteins (2012-07-03),
5. 8173122 - Methods of treatment using antibodies to neutrokine-alpha (2012-05-08),
6. 8071092 - Methods of inhibiting B lymphocytes using antibodies to Neutrokine-alpha (2011-12-06),
7. 8003386 - Tumor necrosis factor receptors 6α and 6β (2011-08-23),
8. 7994284 - Connective tissue growth factor (CTGF-3) polypeptides (2011-08-09),
9. 7964190 - Methods and compositions for decreasing T-cell activity (2011-06-21),
10. 7737257 - Connective tissue growth factor (CTGF-3) (2010-06-15),
11. 7709218 - Tumor necrosis factor receptors 6α and 6β (2010-05-04),
12. 7611846 - Diagnostic methods involving human growth factor huXAG-1 (2009-11-03),
13. 7534428 - Antibodies to tumor necrosis factor receptors 6α and 6β (2009-05-19),
14. 7459531 - 50 Human secreted proteins (2008-12-02),
15. 7381800 - Antibodies to HBIMF63 polypeptide (2008-06-03),

Title: Reinhard Ebner: Pioneering Innovator in Biomedical Technologies

Introduction:

Reinhard Ebner is a distinguished inventor based in Gaithersburg, MD, with an impressive portfolio of 55 patents. His groundbreaking work in the field of biomedical technologies has significantly impacted the healthcare industry.

Latest Patents:

Ebner's latest patents include innovative solutions such as therapeutic peptides with guanylyl cyclase C agonist activity, which are instrumental in treating chronic ideopathic constipation, inflammatory bowel disease, and other related conditions. Additionally, his Neutrokine-alpha antibodies have opened new avenues in diagnosing and treating autoimmune disorders.

Career Highlights:

With a successful tenure at companies like Human Genome Sciences, Inc. and Combimab, Inc., Ebner has been at the forefront of cutting-edge research and development. His inventions have not only garnered recognition but have also contributed significantly to the advancement of medical science.

Collaborations:

During his career, Ebner has collaborated with esteemed professionals in the field, including individuals like Steven M. Ruben and Guo-Liang Yu. These collaborations have been instrumental in driving innovation and fostering a culture of excellence in biomedical research.

Conclusion:

Reinhard Ebner's unwavering dedication to innovation and his remarkable contributions to the field of biomedical technologies have solidified his reputation as a visionary inventor. His patents continue to shape the future of healthcare, offering new hope and possibilities for patients worldwide.Dot

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…